

# AUSTRIA

## Recent and planned developments in pharmaceutical policies 2018

### Special topic: national incentives and derogatory procedures for orphan medicines

#### CHANGES IN PRICING

**Free pricing turns into EU average price reimbursement**  
medicines outside the <<EKO>>\* but financed by social security institutions which reach a turnover of 750,000 Euros (on ex-factory price basis, after 12 months, not calendar year) are reimbursed at EU average price

**1**  
January 2018

#### CHANGES IN REIMBURSEMENT


**2018**  
Prescription fee 6.00  
Euro

#### OTHER CHANGES



#### Electronic Vaccination Record is going to be implemented as pilot project

Decision made by federal and provincial government as well as health insurance funds on 29 June 2018.



#### SPECIAL TOPIC: National Incentives and Derogatory Procedures for Orphan Medicines

##### Availability

- regular meetings between head physicians (sickness funds) and patient advocates in order to ensure access to proper medicines
- measures for further education and training for health professional in order to raise the awareness of rare diseases (professional associations, chamber of physicians, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection responsible) – process started in 2014 (still on-going)

##### Research and Development

- information activities about research funding promotion programmes regarding rare diseases from institutions supporting researchers to raise funds and authorities (e.g. the Federal Ministry for Digital and Economic Affairs); since 2014 on-going

##### Funding

- the process of adaption of coding of orphan diseases (DRG based funding) in the in-patient sector was commenced in 2014 by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (process is still on-going)

##### Pricing & Reimbursement

- no special procedure for medicines for rare diseases (common procedure for all other products; different procedures in the out-patient and in-patient sector)

Incentives has been set in the National Action Plan for Rare Diseases in Austria commissioned by the Federal Ministry of Labour, Social Affairs, Health and Consumer Protection.